Investigating a new target for treatment in Prader-Willi syndrome

Prader-Willi syndrome (PWS) is a rare genetic condition that causes a range of challenges including insatiable hunger, behavioural difficulties, and developmental delays. One of the most difficult aspects of PWS is that there are currently no effective medications to address the core behavioural symptoms. This study looks at whether a medication called acamprosate — normally used to help people with alcohol dependence — could boost levels of a brain chemical called GABA, which helps 'calm' brain activity. Researchers believe that low GABA levels in the brain may contribute to the challenging behaviours seen in PWS. Participants will take acamprosate for a period and then have brain scans (using a specialised MRI technique called MRS) to measure whether GABA levels have increased. A healthy control group without PWS will also participate for comparison. This study is open to adults aged 18 to 30, either with a confirmed genetic diagnosis of PWS or as a healthy control. Participants must not have MRI contraindications (such as metal implants or severe claustrophobia), must not currently be taking GABA-based medications, and must have adequate kidney function. Women who are pregnant or breastfeeding are not eligible.